Journal article

Reverse Remodeling of the Atria After Treatment of Chronic Stretch in Humans. Implications for the Atrial Fibrillation Substrate

B John, MK Stiles, P Kuklik, AG Brooks, ST Chandy, JM Kalman, P Sanders

Journal of the American College of Cardiology | ELSEVIER SCIENCE INC | Published : 2010

Abstract

Objectives: The aim of this report was to study the effect of chronic stretch reversal on the electrophysiological characteristics of the atria in humans. Background: Atrial stretch is an important determinant for atrial fibrillation. Whether relief of stretch reverses the substrate predisposed to atrial fibrillation is unknown. Methods: Twenty-one patients with mitral stenosis undergoing mitral commissurotomy (MC) were studied before and after intervention. Catheters were placed at multiple sites in the right atrium (RA) and sequentially within the left atrium (LA) to determine: effective refractory period (ERP) at 10 sites (600 and 450 ms) and P-wave duration (PWD). Bi-atrial electroanatom..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

This work was presented in part by Dr. John, who received the Young Investigator Award, at the 3rd Asia-Pacific AF Symposium, October 2007, Taipei, Taiwan; and at the Annual Scientific Sessions of the American Heart Association, November 2007, Orlando, Florida; and published in abstract form (Circulation 2007; 116: II438). This work was supported in part by a Grant-in-Aid (G 08A 3646) from the National Heart Foundation of Australia and by the Australia-India Strategic Research Fund. Dr. John is supported by the Biosense-Webster Electrophysiology Scholarship, University of Adelaide. Dr. Stiles is supported by the National Heart Foundation of New Zealand and the Dawes Scholarship, Royal Adelaide Hospital. Drs. Brooks and Sanders are supported by the National Heart Foundation of Australia. Dr. Sanders reports having served on the advisory board of and having received lecture fees and research funding from St. Jude Medical, Bard Electrophysiology, Biosense-Webster, and Medtronic.